Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Jun
27
Today In Oncology
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors
CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo